Curated News
By: NewsRamp Editorial Staff
March 10, 2026
Tonix's TONMYA Shows Rapid Fibromyalgia Pain Relief in New Data
TLDR
- Tonix Pharmaceuticals' TONMYA offers investors an edge as the first new fibromyalgia treatment in 15 years with strong clinical data and a favorable benefit-risk profile.
- TONMYA, a sublingual cyclobenzaprine tablet, demonstrated rapid pain relief in Phase 3 trials with statistically significant results and mild, transient oral cavity reactions as the most common side effects.
- This new fibromyalgia treatment improves patients' quality of life by providing effective pain relief and represents medical progress for a condition with high unmet need.
- Tonix Pharmaceuticals presented data showing their fibromyalgia drug TONMYA provides pain relief nearly four times more likely to benefit patients than cause treatment discontinuation.
Impact - Why it Matters
This news matters because fibromyalgia affects millions worldwide, often causing debilitating chronic pain that significantly impairs quality of life, with limited treatment options available for over 15 years. TONMYA's approval and the new data demonstrating rapid pain relief and a favorable safety profile offer renewed hope to patients and clinicians. The potential expansion into other CNS conditions like major depressive disorder could address additional areas of high unmet need, impacting broader patient populations. For the biotechnology sector and investors, Tonix's progress highlights innovation in CNS and immunology, potentially driving future growth and attracting attention to small-cap companies in this space.
Summary
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully-integrated, commercial-stage biotechnology company, made significant waves at the 8th International Congress on Controversies in Fibromyalgia in Krakow, Poland, with two oral presentations on its flagship medication, TONMYA™ (investigated as TNX-102 SL). The presentations featured compelling post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies. These analyses underscored TONMYA's rapid pain relief and favorable benefit-risk profile for adults suffering from fibromyalgia, a chronic condition marked by widespread pain. The data revealed statistically significant reductions in pain and demonstrated that the likelihood of clinical benefit was nearly four times greater than the risk of discontinuation due to adverse events. As the first new medication approved for fibromyalgia in over 15 years, TONMYA represents a major breakthrough, and it was generally well tolerated, with mild and transient oral cavity reactions being the most commonly reported side effects.
Beyond its success in fibromyalgia, Tonix Pharmaceuticals is leveraging its central nervous system (CNS) commercial infrastructure to maximize the science behind TONMYA. The company is actively exploring its potential in other areas of high unmet medical need, including Phase 2 clinical trials for major depressive disorder and acute stress disorder. Tonix's robust CNS portfolio also includes TNX-2900, which is Phase 2 ready for treating Prader-Willi syndrome, a rare disease. Furthermore, the company is advancing a pipeline of immunology programs, such as the monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. It's important to note that, while promising, these product development candidates are investigational new drugs whose efficacy and safety have not yet been established.
This news was disseminated through the specialized communications platform TinyGems, which is part of the expansive Dynamic Brand Portfolio managed by IBN (InvestorBrandNetwork). TinyGems focuses on innovative small-cap and mid-cap companies, providing them with comprehensive services like access to wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, and broad social media distribution via IBN to millions of followers. For investors and the public seeking the latest updates on Tonix Pharmaceuticals, the company maintains a newsroom accessible through the provided link. This integrated approach ensures that groundbreaking developments from companies like Tonix reach a wide audience of investors, influencers, and consumers, cutting through the information overload in today's market.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix's TONMYA Shows Rapid Fibromyalgia Pain Relief in New Data
